Status:
COMPLETED
Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Pediatric Cancer
Febrile Neutropenia
Eligibility:
All Genders
1-17 years
Brief Summary
In this pilot study the feasibility of continous monitoring of health data with a small, on-skin wearable device (the Everion®, by Biovotion, Zurich) in pediatric patients under chemotherapy for cance...
Detailed Description
No study has proved feasibility of continuous monitoring of health data with a small wearable device such as the device Everion® in pediatric patients. It is not known if children tolerate the device ...
Eligibility Criteria
Inclusion
- Chemotherapy treatment because of any malignancy, expected to last ≥1 months at time of recruitment for myelosuppressive therapy or at least one cycle of myeloablative therapy.
- Age 1 month to \<18 years at time of recruitment
- Written informed consent from patients and/or parents
Exclusion
- Local skin diseases prohibiting wearing of the device.
- Denied written informed consent from patients and/or parent
Key Trial Info
Start Date :
November 29 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 13 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04134429
Start Date
November 29 2019
End Date
January 13 2020
Last Update
July 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Inselspital
Bern, Switzerland, 3010